Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hannah James

Physician Assistant Chattanooga, TN Physician Assistant

NPI 1407203409 CMS profile 10694438

5616 Brainerd Rd Ste 208, Chattanooga, TN 37411

Open in the dashboard

General payments

$10,657

467 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah James of Chattanooga, TN is reported in the CMS Open Payments database as having received $10,657 across 467 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,988 78
2024 General $1,724 68
2023 General $2,998 64
2022 General $1,466 94
2021 General $2,481 163

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah James
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Hannah James were reported at $1,988. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Hannah James Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,481 $132 $37–$438 $132
2022 $1,466 $155 $48–$522 $149
2023 $2,998 $167 $52–$557 $160
2024 $1,724 $178 $55–$600 $164
2025 $1,988 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Xeris Pharmaceuticals, Inc. $2,533 18 payments
  2. Novo Nordisk Inc $834 67 payments
  3. Lilly USA, LLC $825 44 payments
  4. AbbVie, Inc. $758 45 payments
  5. Mannkind Corporation $719 44 payments
  6. Abbott Laboratories $624 37 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $512 31 payments
  8. Sanofi-Aventis U.S. LLC $387 24 payments
  9. Insulet Corporation $354 8 payments
  10. Novartis Pharmaceuticals Corporation $290 15 payments
  11. Other $2,822 134 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,285 463 payments
  2. Consulting Fee $1,864 2 payments
  3. Honoraria $466 1 payment
  4. Education $43 1 payment
Products named General payments · program years 2021–2025
  1. GVOKE HYPOPEN $2,427 12 payments
  2. Ozempic $763 64 payments
  3. RYBELSUS $756 63 payments
  4. AFREZZA $719 44 payments
  5. LINZESS $566 34 payments
  6. CREON $501 32 payments
  7. FreeStyle Libre 3 $449 23 payments
  8. Omnipod $354 8 payments
  9. MOUNJARO $351 18 payments
  10. JARDIANCE $302 19 payments
  11. Other $5,965 323 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

2,057

Median for Physician Assistant: 241

Drug cost

$1,192,743

Median for Physician Assistant: $4,110

Branded share of claims

55.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 178 $278,516
Tresiba Flextouch U-200 Insulin Degludec Brand 56 $121,337
Ozempic Semaglutide Brand 63 $111,248
Jardiance Empagliflozin Brand 77 $90,462
Humalog Kwikpen U-200 Insulin Lispro Brand 12 $66,649
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 43 $64,104
Novolog Flexpen Insulin Aspart Brand 93 $52,998
Trulicity Dulaglutide Brand 33 $52,897
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 21 $51,653
Tresiba Flextouch U-100 Insulin Degludec Brand 43 $45,897

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $496
$496 — —
MOUNJARO
  • Lilly USA, LLC $136
$136 178 —
UNITHROID
  • Amneal Pharmaceuticals LLC $131
$131 14 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $95
$95 — —
ZEPBOUND
  • Lilly USA, LLC $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

467 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record